X4 Pharmaceuticals, Inc. (XFOR)
NASDAQ: XFOR · Real-Time Price · USD
2.990
-0.270 (-8.28%)
At close: Sep 15, 2025, 4:00 PM EDT
2.981
-0.009 (-0.29%)
After-hours: Sep 15, 2025, 7:54 PM EDT
X4 Pharmaceuticals Employees
X4 Pharmaceuticals had 143 employees as of December 31, 2024. The number of employees increased by 50 or 53.76% compared to the previous year.
Employees
143
Change (1Y)
50
Growth (1Y)
53.76%
Revenue / Employee
$229,189
Profits / Employee
-$713,119
Market Cap
67.15M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 143 | 50 | 53.76% |
| Dec 31, 2023 | 93 | 23 | 32.86% |
| Dec 31, 2022 | 70 | -13 | -15.66% |
| Dec 31, 2021 | 83 | 11 | 15.28% |
| Dec 31, 2020 | 72 | 14 | 24.14% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
XFOR News
- 4 weeks ago - X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - X4 Pharmaceuticals Announces Closing of Upsized $85 Million Private Placement - GlobeNewsWire
- 4 weeks ago - X4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board Leadership - GlobeNewsWire
- 3 months ago - X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA) - GlobeNewsWire
- 3 months ago - X4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDA - GlobeNewsWire
- 4 months ago - X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress - GlobeNewsWire
- 4 months ago - X4 Pharmaceuticals, Inc. (XFOR) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewsWire